Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030567 (
Parkinson's disease
)
63,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Parkin is an ubiquitin-protein ligase (E3), mutations of which cause juvenile onset - autosomal recessive
Parkinson's disease
, and result in reduced enzymic activity. In contrast, increased levels are protective against mitochondrial dysfunction and neurodegeneration, the mechanism of which is largely unknown. In this study, 2-DE and MS proteomic techniques were utilised to investigate the effects of increased Parkin levels on protein expression in whole cell lysates using in an inducible Parkin expression system in HEK293 cells, and also to isolate potential interactants of Parkin using tandem affinity purification and MS. Nine proteins were significantly differentially expressed (+/-2-fold change; p<0.05) using 2-DE analysis. MS revealed the identity of these proteins to be ACAT2, HNRNPK, HSPD1, PGK1, PRDX6, VCL, VIM, TPI1, and IMPDH2. The first seven of these were reduced in expression. Western blot analysis confirmed the reduction in one of these proteins (HNRNPK), and that its levels were dependent on 26S proteasomal activity. Tandem affinity purification/MS revealed 14 potential interactants of Parkin; CKB, DBT, HSPD1, HSPA9, LRPPRC, NDUFS2, PRDX6, SLC25A5, TPI1, UCHL1,
UQCRC1
, VCL, YWHAZ, YWHAE. Nine of these are directly involved in mitochondrial energy metabolism and glycolysis; four were also identified in the 2-DE study (HSP60, PRDX6, TPI1, and VCL). This study provides further evidence for a role for Parkin in regulating mitochondrial activity within cells.
...
PMID:Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. 1972 78
The aim of this study was to screen the genes related to the pathogenesis of major depression disorder (MDD) by bioinformatics. Taking GSE98793 chip data from GEO public database of National Biotechnology Information Center (NCBI) website as the research object, 116 differentially expressed genes (DEGs) were screened by R language limma package. Among the 116 DEGs, 66 genes were up-regulated and 50 down-regulated. The results of gene functional annotation analysis of Gene Ontology (GO) showed that the DEGs were mainly distributed in mitochondria intima and mitochondria. They were involved in copper ion binding, cysteine-type endopeptidase activity, the cell response of interleukin-1, protein processing and other biological processes. KEGG pathway enrichment analysis results showed that the DEGs were mainly concentrated in oxidative phosphorylation,
Parkinson's disease
, non-alcoholic fatty liver disease, Alzheimer's disease and Huntington's disease etc. The results of protein interaction network analysis showed that there were interactions among proteins encoded by 54 DEGs. Combined with the analysis results of the above methods, 11 key genes were screened out, including
UQCRC1
, GZMB, NDUFB9, NSF, SLC17A5, CTSH, NDUFB10, UQCR10, ATOX1, CST7 and CTSW, which could be used as candidate genes for the diagnosis and treatment of MDD. Taken together, the key genes were obtained by analyzing the microarray and the DEGs of MDD in the present study, which would provide important clues for revealing the molecular mechanism and clinical targeted therapy of depression.
...
PMID:[Bioinformatics analysis of genes related to pathogenesis of major depression disorder]. 3011 61
Recently, a novel variant p.Y314S in
UQCRC1
has been implicated as pathogenic in
Parkinson's disease
(PD). In the present study, we aimed to examine the association of
UQCRC1
with PD in large cohorts of European origin. We examined common and rare genetic variation in
UQCRC1
using genome-wide association study data from the International
Parkinson Disease
Genomics Consortium, including 14,671 cases and 17,667 controls, and whole-genome sequencing data from the Accelerating Medicines Partnership-
Parkinson's disease
initiative, including 1647 patients with PD and 1050 controls. No common variants were consistently associated with PD, and a variety of burden analyses did not reveal an association between rare variants in
UQCRC1
and PD. Therefore, our results do not support a major role for
UQCRC1
in PD in the European population, and additional studies in other populations are warranted.
...
PMID:Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans. 3324 4